<DOC>
	<DOCNO>NCT01454349</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy single treatment PRX302 treatment Benign Prostatic Hyperplasia ( BPH ) compare placebo .</brief_summary>
	<brief_title>Study PRX302 Lower Urinary Tract Symptoms Due Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Lower Urinary Tract Symptoms ( LUTS ) attributable BPH ≥6 month Written inform consent prior enrollment study IPSS ≥12 Prostate volume 30 100 mL determine TRUS Maximum urine flow ( Qmax ) 4 15 mL/sec Refractory , intolerant refuse use alphablockers and/or 5 alphareductase inhibitor Unwilling unable undergo conventional surgical available minimally invasive treatment Blood PSA value &lt; 10 ng/mL Inability void least 125 mL urine PVR volume &gt; 200 mL Presence history certain condition could interfere study result endanger subject Use certain prescribed medication could interfere study result</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>Lower urinary tract symptom ( LUTS )</keyword>
</DOC>